Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Administration of a recombinant factor viia in patients undergoing liver transplantation for fulminant hepatic failure

K Jarosz, M Czupryńska, J Andrzejewska, M Wasilewicz, M Post, J Lubikowski, M Wójcicki, P Milkiewicz

Ann Transplant 2009; 14(1): 41-41 :: ID: 880347


Background: Fulminant hepatic failure (FHF) is associated with profound clotting disorder leading to the risk of a major blood loss during liver transplantation (LTx). Application of a recombinant factor VIIa (rFVIIa) which promptly corrects clotting abnormalities remains controversial in the LTx setting. Aim: Retrospective analysis of the effect of rFVIIa on the prothrombin time (PT) and other perioperative parameters in a group of patients transplanted for FHF in our centre.
Material/Methods: Nineteen consecutive patients (9 males, 10 females mean age 33±13) were studied. Clinical diagnoses were as follows: Wilson's - 8 patients; Non-A-non-B hepatitis - 6 patients, Amanita toxicity - 5 patients. All subjects received rFVIIa in the mean dose of 54±16 mcg/kg body mass 10 minutes before skin incision. The PT was measured 15 minutes and 12 hours later. Data are presented as mean ±SD and were analysed with StatView program. P values <0.05 were considered significant.
Results: Rapid correction of PT was observed in all patients (mean PT before injection 37±14 vs. 14±3 after 15 min; p<0.0001). Twelve hours after injection PT was 19±5 (p<0.0001 vs. before injection and p<0.0007 vs. 15 min after injection). Two patients died on 1st and 19[sup]th[/sup] day after LTx. Mean RBC
requirement was 5±4U and FFP was 11±5U. Mean surgery time was 527±126
min and ITU stay 8±9 days. None of the patients developed thromboembolic complications.
Conclusions: Administration of rFVIIa causes rapid improvement of the PT
shortly after injection. It was safe and not associated with any thromboembolic events in our series.

Keywords: Liver Transplantation

Add Comment 0 Comments

In Press

12 Feb 2024 : Original article  

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...

Ann Transplant In Press; DOI: 10.12659/AOT.942767  

21 Feb 2024 : Original article  

Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians

Ann Transplant In Press; DOI: 10.12659/AOT.943498  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358